TY - JOUR
KW - Humans
KW - Male
KW - *Pulmonary Disease, Chronic Obstructive/epidemiology/complications
KW - Female
KW - Case-Control Studies
KW - Aged
KW - *Atrial Fibrillation/epidemiology
KW - *Heart Failure/epidemiology
KW - *Atrial Flutter/epidemiology
KW - Middle Aged
KW - Risk Factors
KW - Aged, 80 and over
KW - *Hospitalization/statistics & numerical data
KW - Disease Progression
KW - Logistic Models
KW - Arrhythmia
KW - Atrial fibrillation
KW - Cardiovascular disease
KW - Chronic Obstructive Pulmonary Disease Exacerbations
KW - Electronic Health Records
KW - epidemiology
KW - Flutter
KW - heart failure
AU - E. Graul
AU - C. Nordon
AU - K. Rhodes
AU - S. Menon
AU - Al Ammouri
AU - C. Kallis
AU - A. Ioannides
AU - H. Whittaker
AU - N. Peters
AU - J. Quint
AD - School of Public Health, Imperial College London, 86 Wood Lane, London, W12 0BZ, UK.
Biopharmaceuticals Medical, AstraZeneca, Academy House, 136 Hills Rd, Cambridge, CB2 8PA, UK.
Medical and Scientific Affairs, AstraZeneca, 2 Pancras Sq, London, N1C 4AG, UK.
National Heart and Lung Institute, Imperial College London, 86 Wood Lane, London, W12 0BZ, UK.
School of Public Health, Imperial College London, 86 Wood Lane, London, W12 0BZ, UK. j.quint@imperial.ac.uk.
AN - 38704538
BT - BMC Pulm Med
C2 - PMC11069200
DO - 10.1186/s12890-024-03035-4
DP - NLM
ET - 2024/05/05
LA - eng
M1 - 1
N1 - 1471-2466
Graul, Emily L
Nordon, Clementine
Rhodes, Kirsty
Menon, Shruti
Al Ammouri, Mahmoud
Kallis, Constantinos
Ioannides, Anne E
Whittaker, Hannah R
Peters, Nicholas S
Quint, Jennifer K
Journal Article
England
BMC Pulm Med. 2024 May 4;24(1):221. doi: 10.1186/s12890-024-03035-4.
PY - 2024
SN - 1471-2466
EP - 221
T2 - BMC Pulm Med
TI - Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study
VL - 24
ER -